title: The dengue vaccine pipeline: Implications for the future of dengue control.
abstract: Dengue has become the most rapidly expanding mosquito-borne infectious disease on the planet, surpassing malaria and infecting at least 390 million people per year. There is no effective treatment for dengue illness other than supportive care, especially for severe cases. Symptoms can be mild or life-threatening as in dengue hemorrhagic fever and dengue shock syndrome. Vector control has been only partially successful in decreasing dengue transmission. The potential use of safe and effective tetravalent dengue vaccines is an attractive addition to prevent disease or minimize the possibility of epidemics. There are currently no licensed dengue vaccines. This review summarizes the current status of all dengue vaccine candidates in clinical evaluation. Currently five candidate vaccines are in human clinical trials. One has completed two Phase III trials, two are in Phase II trials, and three are in Phase I testing.
authors.affiliation: Department of Epidemiology, School of Public Health, University of Washington, Seattle, WA, USA; Vaccine and Infectious Diseases Division, Fred Hutchinson Cancer Research Center, Seattle, WA, USA. Electronic address: laurenms@uw.edu.
authors.forename: Lauren M
authors.initials: LM
authors.lastname: Schwartz
authors.affiliation: Department of Biostatistics, School of Public Health, University of Washington, Seattle, WA, USA; Vaccine and Infectious Diseases Division, Fred Hutchinson Cancer Research Center, Seattle, WA, USA; Center for Inference and Dynamics of Infectious Diseases, Seattle, WA, USA.
authors.forename: M Elizabeth
authors.initials: ME
authors.lastname: Halloran
authors.affiliation: Department of International Health, Johns Hopkins Bloomberg School of Public Health, Baltimore, MD, USA.
authors.forename: Anna P
authors.initials: AP
authors.lastname: Durbin
authors.affiliation: Center for Inference and Dynamics of Infectious Diseases, Seattle, WA, USA; Department of Biostatistics, College of Public Health and Health Professions and College of Medicine, University of Florida, Gainesville, FL, USA.
authors.forename: Ira M
authors.initials: IM
authors.lastname: Longini
mesh_terms: D002986:Clinical Trials as Topic; D003715:Dengue / Q000453:epidemiology* / Q000517:prevention & control*; D053059:Dengue Vaccines / Q000276:immunology* / Q000302:isolation & purification*; D055808:Drug Discovery / Q000639:trends*; D006801:Humans
chemical_list: D053059:Dengue Vaccines
keywords: Clinical trial; Dengue vaccine; Dengue virus; Efficacy; Vaccine